Remove 2002 Remove Access Remove Clinical Trials Remove Patients
article thumbnail

Press Release: Launch of the Psychedelic Access and Research European Alliance – PAREA

Cannabis Law Report

PAREA is a non-profit, multistakeholder and multidisciplinary partnership bringing together patient organizations, medical associations, scientific societies, psychedelic foundations, and the for-profit sector. The good news is that innovations that completely change the lives of patients continue to emerge. David Nutt and Prof.

Access 52
article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. On May 3, 2021, our study of MDMA-assisted therapy for PTSD achieved successful results for patients with severe, chronic PTSD.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105
article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

Turning down activity in the DMN allows better access to new areas of the brain, which can boost creativity and improve problem solving. Using integration or psychotherapy along with these medicines allows patients to incorporate the positive effects permanently. As such, there have been numerous clinical trials using ketamine.

History 119
article thumbnail

Paper: The transition of cannabis into the mainstream of Australian healthcare: framings in professional medical publications

Cannabis Law Report

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. The review, however, did not cover patient access to medicinal cannabis. Bonini et al.

article thumbnail

First ethics at MAPS in question and now Australia’s Mind Medicine look to have some serious integrity issues too

Cannabis Law Report

Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. The charity was eventually instructed to pull an advertisement for the study by the ethics committee that conditionally approved the trial.

article thumbnail

Why we haven’t cured cancer

Otherside Farms

Medscape: Medscape Access. A pilot clinical study of Delta(9)-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Clinical Studies and Case Reports. THC tested against brain tumour in pilot clinical study (news – 2006). news – 2002). Clinical Studies and Case Reports.